Nesfatin-1 has been reported to suppress cell proliferation of adrenocortical carcinoma cells and epithelial ovarian carcinoma [15, 16], while NUCB2 was shown to promote cell proliferation and invasion of breast carcinoma cells, and was associated with unfavorable clinical outcomes in prostate and breast cancer [13, 18]. Here, NUCB2 is linked to breast cancer.